Elan 4Q Revenues: $271.0 million (-12%) 4Q Loss: $134.7 million (loss of $52.2 million 4Q10) FY Revenues: $1.2 billion (+7%) FY Earnings: $560.5 million (loss of $324.7 million FY10) Comments: Global in-market sales of Tysabri were up 23% to $1.5 billion in 2011, which helped offset the loss of revenues from a number of EDT legacy products including Azactam, Maxipime and Prialt, which contributed $41.5 million in 2010. Loss in the quarter includes charges of $22.0 million, a charge on debt ...